Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Selection and characterization of HER2/neu-binding affibody ligands.

Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Ståhl S.

Protein Eng Des Sel. 2004 May;17(5):455-62. Epub 2004 Jun 18.

PMID:
15208403
2.

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.

Friedman M, Lindström S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H, Gedda L, Frejd FY, Ståhl S.

Biotechnol Appl Biochem. 2009 Aug 21;54(2):121-31. doi: 10.1042/BA20090096.

PMID:
19492986
3.

Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.

Friedman M, Nordberg E, Höidén-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J, Ståhl S.

Protein Eng Des Sel. 2007 Apr;20(4):189-99. Epub 2007 Apr 23.

PMID:
17452435
4.

Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.

Wållberg H, Löfdahl PK, Tschapalda K, Uhlén M, Tolmachev V, Nygren PK, Ståhl S.

Protein Expr Purif. 2011 Mar;76(1):127-35. doi: 10.1016/j.pep.2010.10.008. Epub 2010 Oct 26.

PMID:
21029777
5.

Selection and characterization of Affibody ligands to the transcription factor c-Jun.

Lundberg E, Brismar H, Gräslund T.

Biotechnol Appl Biochem. 2009 Jan;52(Pt 1):17-27. doi: 10.1042/BA20070178.

PMID:
18260830
6.

Selection and characterization of an HIV-1 gp120-binding affibody ligand.

Wikman M, Rowcliffe E, Friedman M, Henning P, Lindholm L, Olofsson S, Ståhl S.

Biotechnol Appl Biochem. 2006 Sep;45(Pt 2):93-105.

PMID:
16712522
7.

Structural basis for high-affinity HER2 receptor binding by an engineered protein.

Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsén L, Härd T.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15039-44. doi: 10.1073/pnas.1005025107. Epub 2010 Aug 9.

8.

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment.

Belimezi MM, Papanastassiou D, Merkouri E, Baxevanis CN, Mamalaki A.

Cancer Immunol Immunother. 2006 Sep;55(9):1091-9. Epub 2005 Nov 26.

PMID:
16311733
9.

On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.

Orlova A, Wållberg H, Stone-Elander S, Tolmachev V.

J Nucl Med. 2009 Mar;50(3):417-25. doi: 10.2967/jnumed.108.057919. Epub 2009 Feb 17.

10.

[Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].

Fan YX, Luo RC, Fang YX, Yan X, Lu CW.

Ai Zheng. 2006 Apr;25(4):443-6. Chinese.

PMID:
16613677
11.

An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein.

Hansson M, Ringdahl J, Robert A, Power U, Goetsch L, Nguyen TN, Uhlén M, Ståhl S, Nygren PA.

Immunotechnology. 1999 Mar;4(3-4):237-52.

PMID:
10231093
12.

177Lu-CHX-A''-DTPA-ABD-Affibody (ZHER2:342)2.

Zhang H.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Jul 25 [updated 2008 Aug 27].

13.

Design of an optimized scaffold for affibody molecules.

Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjöberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Höidén-Guthenberg I, Galli J, Jonasson P, Abrahmsén L.

J Mol Biol. 2010 Apr 30;398(2):232-47. doi: 10.1016/j.jmb.2010.03.002. Epub 2010 Mar 10.

PMID:
20226194
14.

Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro.

Jonsson A, Wållberg H, Herne N, Ståhl S, Frejd FY.

Biotechnol Appl Biochem. 2009 Aug 17;54(2):93-103. doi: 10.1042/BA20090085.

PMID:
19545237
15.

Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides.

Grönwall C, Jonsson A, Lindström S, Gunneriusson E, Ståhl S, Herne N.

J Biotechnol. 2007 Jan 30;128(1):162-83. Epub 2006 Sep 27.

PMID:
17088007
16.

Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY.

Cancer Res. 2006 Apr 15;66(8):4339-48.

17.

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM.

Mol Immunol. 1999 May;36(7):433-45.

PMID:
10449096
18.

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H.

Cancer Res. 2009 May 15;69(10):4270-6. doi: 10.1158/0008-5472.CAN-08-2861. Epub 2009 May 12.

19.

Alexa Fluor 750-albumin-binding domain-fused-(ZHER2:342)2 Affibody.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Dec 16 [updated 2011 Apr 4].

20.

In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.

Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Ståhl S, Carlsson J.

Cancer Biother Radiopharm. 2005 Jun;20(3):239-48.

PMID:
15989469

Supplemental Content

Support Center